Nanoparticle-mediated siRNA delivery systems for cancer therapy

31Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The small interfering RNA (siRNA)-based therapeutics have raised great attention since the first RNA interference (RNAi)-derived drug, patisiran, was approved by the US Food and Drug Administration, which represented a landmark in the field of gene therapy. Given the properties of interfering disease-associated gene expression, RNAi machinery is regarded as an essential factor for preparing precise medicine. However, over the past few years, siRNA drugs are undergoing a period of clinical translation, in which the major hurdle is the limited efficient delivery strategies. Therefore, this mini-review mainly focuses on describing the state-of-the-art of the nanoscale platforms for delivering siRNA payloads, also addressing their applications in cancer therapy. Finally, the status of siRNA drugs under clinical trials is discussed, providing a comprehensive understanding on the field of oligonucleotide-mediated therapeutics.

Cite

CITATION STYLE

APA

Gao, H., Cheng, R., & A. Santos, H. (2021, June 1). Nanoparticle-mediated siRNA delivery systems for cancer therapy. VIEW. John Wiley and Sons Inc. https://doi.org/10.1002/VIW.20200111

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free